Ex Vivo Human Skin Model for Vaccine Potential Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining the vaccine potential of compositions rely on animal models, which are inefficient and leave uncertainties about their effectiveness in humans, as they fail to accurately assess the activation of antigen-presenting cells and inflammatory responses.
Innovation Solution
An ex vivo human skin model is developed for subcutaneous injection of vaccine compositions, allowing for the determination of antigen-presenting cell activation, migration, and inflammatory potential, enabling the evaluation of vaccine potential without animal testing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If animal models are used to determine vaccine potential, then testing can be performed, but the results leave uncertainties about effectiveness in humans and do not accurately assess antigen-presenting cell activation
Solution Approach 1:
The patent segments the complex immune response assessment into specific measurable components: antigen-presenting cell activation markers (HLA-DR, CD80, CD86), cytokine production (IL-6, TNF-alpha, IL-10), and mast cell degranulation. This segmentation allows for precise measurement of individual immune parameters that collectively predict human vaccine response accuracy
Solution Approach 2:
The patent uses human skin explants as an intermediary model between animal testing and human clinical trials. The skin explant contains functional antigen-presenting cells, mast cells, and immune signaling pathways that mirror human immune responses, serving as a reliable mediator to predict human vaccine effectiveness without requiring animal models
2Productivity
If animal models are used for vaccine testing, then testing capability is provided, but the device complexity and time requirements increase
Solution Approach 1:
The patent prepares human skin explants in advance with cultured antigen-presenting cells and mast cells before vaccine testing. This preliminary preparation ensures that all immune components are ready and functional, allowing immediate testing upon vaccine application and significantly reducing the time required for vaccine potential determination compared to animal models
3Measurement precision
If animal models are used to assess vaccine potential, then testing can be performed, but inflammatory response assessment is inaccurate
Solution Approach 1:
The human skin explant model contains endogenous mast cells and antigen-presenting cells that naturally respond to vaccine antigens and adjuvants. These cells self-regulate inflammatory responses through their inherent biological functions, providing accurate measurement of inflammatory potential without requiring external animal systems that cannot properly replicate human inflammatory pathways
Data Source
AI summary
The present invention relates to an in vitro method intended to determine the vaccine potential of a composition comprising the steps of: ia) transcutaneous administration of the composition to a skin explant, comprising the epidermis, dermis and skin appendages as well as a thickness of at least 5 millimeters of hypodermis; ib) determination of the activation status of antigen-presenting cells within the skin explant; and ii) determination of the vaccine potential of the composition.